--- a
+++ b/clusters/9knumclustersv2/clust_1514.txt
@@ -0,0 +1,37 @@
+Bortezomib:  days
+Patients with hypersensitivity to bortezomib, boron or mannitol.
+Known hypersensitivity to Velcade, boron, or mannitol
+Current or anticipated use of other investigational agents; NOTE the following clarification for this study:\r\n* Prohibited concurrent therapy: \r\n** Participation in clinical trials with other investigational agents, not included in this trial, within  days of the start of this trial until  weeks after subject has received the last dose of bortezomib for mobilization\r\n** Hypersensitivity to bortezomib, boron or mannitol or G-CSF
+Have a history of allergic (anaphylactic) sensitivity to bortezomib, boron or mannitol
+Patient with hypersensitivity to bortezomib, boron or dexamethasone
+Patient has hypersensitivity to bortezomib, boron, or mannitol
+Known hypersensitivity to any of the following: bortezomib, boron, mannitol
+Previous history of hypersensitivity to bortezomib, boron, or mannitol; known hypersensitivity to the components of study drug or its analogs
+Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol
+Participant who has hypersensitivity to bortezomib, boron, or mannitol
+Known intolerance/hypersensitivity to IMiDs, dexamethasone, boron or mannitol, sucrose, histidine or polysorbate .
+Patient has hypersensitivity to bortezomib, boron or mannitol
+Patient has hypersensitivity to VELCADE (bortezomib), boron, or mannitol
+Patients must not have hypersensitivity to bortezomib, boron or mannitol
+History of allergic reaction/hypersensitivity attributed to compounds containing boron, mannitol, polysorbate  or sodium citrate dehydrate
+Patient has hypersensitivity to bortezomib, boron, or mannitol
+Known hypersensitivity to bortezomib, boron, or mannitol
+Known allergy to bortezomib, boron, or mannitol
+Known hypersensitivity to bortezomib, boron, or any of the other agents utilized in this protocol
+Patient has hypersensitivity to bortezomib, boron, or mannitol
+Hypersensitivity to boron or mannitol, or compounds containing these components
+Patient has hypersensitivity to bortezomib, boron or mannitol
+History of allergic reactions to compounds containing boron, mannitol, VELCADE
+Hypersensitivity to bortezomib, boron, or mannitol
+Patient has hypersensitivity to bortezomib, boron, mannitol, gemcitabine, or doxorubicin. Gemcitabine skin rash that be controlled by short course steroids is allowed.
+No history of hypersensitivity to bortezomib, boron or mannitol
+Patient has hypersensitivity to bortezomib, boron, or mannitol
+Patient has hypersensitivity to bortezomib, boron, or mannitol
+Hypersensitivity to VELCADE, boron, mannitol, or any other component of protocol therapy
+Known hypersensitivity to bortezomib, boron, or mannitol
+Patients with hypersensitivity to carfilzomib, Velcade, boron, or mannitol.
+Patient has hypersensitivity to bortezomib, boron or mannitol
+Patient has a history of allergic reaction attributable to bortezomib or other compounds containing boron or mannitol (Phase b and a only)
+a. bortezomib
+Patients with hypersensitivity to bortezomib, boron or mannitol
+Patients with hypersensitivity to bortezomib, boron or mannitol